Enhanced muscle uptake of chemically optimized miR-23b antisense oligonucleotides as lead compounds for myotonic dystrophy type 1

Key Points

• To explore the muscle uptake of chemically optimized miR-23b antisense oligonucleotides as potential treatments for myotonic dystrophy type 1.
• Utilization of chemically optimized miR-23b antisense oligonucleotides
• Assessment of muscle uptake in animal models
• Comparative analysis of oligonucleotide effectiveness
• Significantly enhanced muscle uptake of miR-23b oligonucleotides observed
• Positive correlation between oligonucleotide optimization and muscle delivery
• Potential therapeutic benefits indicated for myotonic dystrophy type 1 treatment